Roving Reporter Asks: How Is Cell and Gene Therapy Manufacturing Becoming More Scalable?

IBTV speaks with industry leaders at ASGCT 2026 about the technologies, processes, and manufacturing strategies helping advanced therapies progress toward commercial scale

September 18, 2026
2 min

The Medicine Maker

At a Glance

Category	Detail
Condition	Cell and Gene Therapy Manufacturing
Key Mechanisms	Stable cell lines, process intensification, AI-driven process modeling, operational excellence, quality-by-design
Target Population	Patients requiring cell and gene therapies
Care Setting	Life sciences industry and manufacturing environments

Key Highlights

Flexible manufacturing models are crucial for adapting to therapeutic modalities
Regulatory flexibility and data-led process control are important for commercialization
Analytical technologies are improving production quality

Guideline-Based Recommendations

Diagnosis

Management

Monitoring & Follow-up

Risks

Patient & Prescribing Data

Patients requiring cell and gene therapies

Off-the-shelf therapies are being considered for large-scale commercialization

Roving Reporter Asks: How Is Cell and Gene Therapy Manufacturing Becoming More Scalable?

Clinical Scorecard: Roving Reporter Asks: How Is Cell and Gene Therapy Manufacturing Becoming More Scalable?

At a Glance

Key Highlights

Guideline-Based Recommendations

Diagnosis

Management

Monitoring & Follow-up

Risks

Patient & Prescribing Data

Clinical Best Practices

Related Resources & Content

Original Source(s)

Roving Reporter Asks: How Is Cell and Gene Therapy Manufacturing Becoming More Scalable?

Related Content

Musings from The Power List: Dajun Yang

The evolution of RTOG and NRG Oncology CNS tumors clinical trials

Multi-omics profiling reveals sphingolipid metabolism reprogramming of tumor-conditioned MDSCs in cervical cancer